Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases†
Version of Record online: 6 MAR 2013
Copyright © 2012 American Association for the Study of Liver Diseases
Volume 58, Issue 1, pages 409–421, July 2013
How to Cite
Masyuk, T. V., Radtke, B. N., Stroope, A. J., Banales, J. M., Gradilone, S. A., Huang, B., Masyuk, A. I., Hogan, M. C., Torres, V. E. and LaRusso, N. F. (2013), Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases. Hepatology, 58: 409–421. doi: 10.1002/hep.26140
Conflict of interest: Partial financial support for this study was provided by Novartis USA (i.e., animal housing, cost of chemicals and supplies). Novartis was permitted to review the data before the article was written but the final decision on content and result interpretation was exclusively retained by the authors.
- Issue online: 24 JUN 2013
- Version of Record online: 6 MAR 2013
- Accepted manuscript online: 21 NOV 2012 03:00PM EST
- Manuscript Accepted: 6 NOV 2012
- Manuscript Received: 4 MAY 2012
- NIH. Grant Numbers: DK24031, DK44863, EB000305, CA112281, P30DK084567
- NIDDK. Grant Number: P30DK090728
- National Disease Research Interchange (NDRI)
- Novartis USA
Additional Supporting Information may be found in the online version of this article.
|HEP_26140_sm_SuppFig1.tif||341K||Supporting Information Figure 1.|
|HEP_26140_sm_SuppTables.doc||58K||Supporting Information Tables|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.